MGNX - マクロジェニクス （MacroGenics Inc.）

MacroGenics Inc. (NASDAQ:MGNX) closed Wednesday at $5.69 per share, up from $5.62 a day earlier. While MacroGenics Inc. has overperformed by 1.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MGNX fell by -65.01%, with highs and lows ranging from $17.30 to $2.13, whereas the simple […]

MacroGenics Inc. (NASDAQ:MGNX)’s traded shares stood at 0.49 million during the last session, with the company’s beta value hitting 2.07. At the close of trading, the stock’s price was $5.94, to imply an increase of 0.68% or $0.04 in intraday trading. The MGNX share’s 52-week high remains $17.66, putting it -197.31% down since that peak … What Could Change After MacroGenics Inc. (NASDAQ: MGNX) Gains 64.14% From The High-Point? Read More »

In last trading session, MacroGenics Inc. (NASDAQ:MGNX) saw 1.39 million shares changing hands with its beta currently measuring 2.07. Company’s recent per share price level of $6.17 trading at -$0.01 or -0.16% at ring of the bell on the day assigns it a market valuation of $384.02M. That closing price of MGNX’s stock is at … MacroGenics Inc. (NASDAQ:MGNX) Shares Rebounded 65.48% From Their Lows – But Can They Continue? Read More »

Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU ) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday. Citigroup slashed the price target on MacroGenics, Inc. (NASDAQ: MGNX ) from … Full story available on Benzinga.com

MacroGenics (MGNX) has garnered attention on Wall Street this week, with Citi downgrading the commercial-stage biotech on Wednesday to Neutral from Buy after an upgrade from Guggenheim…

MacroGenics Inc. (NASDAQ:MGNX) has a beta value of 2.06 and has seen 1.3 million shares traded in the last trading session. The company, currently valued at $280.81M, closed the last trade at $5.10 per share which meant it gained $0.55 on the day or 12.09% during that session. The MGNX stock price is -450.78% off … Small Cap Stock MacroGenics Inc. (MGNX) Is A Buy – Analysts Read More »

MacroGenics Inc (NASDAQ: MGNX ) announced a corporate restructuring involving a 15% workforce reduction , closure of an R&D facility, and closure of a manufacturing site. After discontinuing a Phase 2 study for enoblituzumab , a program that was upside to estimates, the company''s pipeline efforts are more narrowly focused on MGC018, lorigerlimab, … Full story available on Benzinga.com

MGNX earnings call for the period ending June 30, 2022.

MacroGenics, Inc. (NASDAQ:NASDAQ:MGNX) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig -…

Macrogenics (NASDAQ: MGNX ) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Macrogenics beat estimated earnings by 30.93%, reporting an EPS … Full story available on Benzinga.com

During the last session, MacroGenics Inc. (NASDAQ:MGNX)’s traded shares were 1.2 million, with the beta value of the company hitting 2.22. At the end of the trading day, the stock’s price was $3.33, reflecting an intraday gain of 3.10% or $0.1. The 52-week high for the MGNX share is $29.16, that puts it down -775.68 … MacroGenics Inc. (NASDAQ: MGNX): Can A Stock That’s Down -79.25% YTD Still Be Considered In Loss Territory? Read More »

Investors like that a key insider is buying shares of the biotech.

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY ) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. Valneva SE (NASDAQ: VALN ) gained 79.4% to $24.60. Pfizer will invest €90.5 million ($95 million) for an 8.1% stake in Valneva, as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15. BlackSky Technology Inc. (NYSE: BKSY ) shares jumped 26.4% to $2.5650. BlackSky won a 5-year joint Artificial Intelligence Center contract for AI data readiness. Phoenix New Media Limited (NYSE: FENG ) gained 26.2% to $5.88. Argo Blockchain plc (NASDAQ: ARBK ) jumped 23.9% to $4.66. PermRock Royalty Trust (NYSE: PRT ) gained 22.3% to $8.61. Revlon, Inc. (NYSE: REV ) rose 22.3% to $4.56. Revlon shares jumped 91% on Friday following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. Hallador Energy Company (NASDAQ: HNRG ) gained 20.8% to $7.31. MacroGenics, Inc.

MacroGenics Inc. (NASDAQ:MGNX) concluded the trading at $2.80 on Friday, June 10, with a fall of -8.79% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.07 and 5Y monthly beta was reading 2.11 with its price kept floating in the range … MacroGenics Inc. (MGNX): Worth A Little Bit At $2.80 Read More »

New York, USA, June 08, 2022 (GLOBE NEWSWIRE) -- Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a significant unmet medical need. Advanced Cervical Cancer Pipeline involves 75+ key companies continuously working towards developing 75+ Advanced Cervical Cancer treatment therapies. DelveInsight''s '' Advanced Cervical Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Advanced Cervical Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Cervical Cancer pipeline domain. Key Takeaways from the Advanced Cervical Cancer Pipeline Report DelveInsight''s Advanced Cervical Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.